The 23% Growth Nobody Will Cheer About Yet
Revenue surged 22.6% year-on-year, but net profit margin collapsed to 7.7%, well below the 12%–13% target. Commodity inflation explains the bulk of it, but margin recovery timing remains vague and execution risk is rising.
₹344.7 Cr
+22.6% YoY, +11.4% QoQ
₹26.9 Cr
+7.7% YoY, −2.4% QoQ
7.7%
vs 12%–13% target
10.9%
Gross margin 34.2%, inflation-hit
ADOR Welding's Q2 FY27 result is a textbook case of revenue momentum masking margin compression. The company reported 22.6% year-on-year revenue growth and stood above macro (IIP/GDP growth), backed by strong infrastructure, power, and shipbuilding capex cycles across India. But the net profit margin collapsed to 7.7% from the stated target of 12%–13%, and worse, net profit actually declined 2.4% sequentially despite revenue jumping 11.4% quarter-on-quarter. That gap — growth without profit leverage — is the story of the quarter.
The inflation narrative, and what it holds
Management's diagnosis is credible. Steel costs jumped 7%–8% quarter-on-quarter, freight spiked, and PCB/electronics inflation hit across the supply chain. The MD attributed roughly 80% of the margin dip to these commodity headwinds and only 20% to deliberate growth-stage investment (accepting lower short-term margins for volume). The numbers square: gross margin fell to 34.2%, pulled down by input cost pressure, not operational mismanagement.
The catch: the timing of margin recovery remains 'early days Q3'. Price hikes are underway across customer tiers (Tier 1, 2, 3 segments), but the lag between cost realization and contract repricing is real. Sequential profit decline despite 11.4% revenue growth shows the pass-through is not yet visible in the bottom line. No specific month or magnitude was given for when the 12%–13% EBITDA margin target will recover.
Revenue grew 23% YoY to ₹345 crores
SupportedDelivered ₹344.7 Cr, +22.6% YoY
80% of margin dip is inflation; 20% is growth strategy
SupportedQoQ revenue +11.4%, PAT −2.4%. Margin compression real; attribution plausible.
On track for ₹2,000 crore FY27 aspiration
OverstatedH1 = ₹654 Cr. At 22%+ growth, run-rate suggests ₹900–950 Cr FY27, not ₹2,000 Cr.
EBITDA grew 9% in Q2; H1 EBITDA margin 11.2%
OverstatedDelivered OPM 10.9%, NPM 7.7%. Trajectory below 12%–13% target; growth modest.
What changed on this call
Margin recovery timing deferred to 'early days Q3' (was 100–200 bps improvement)
Capex guidance held at ₹30–35 Cr FY27 (within prior ₹30–40 Cr range); next 2 years ₹60–70 Cr
Flares/Process Equipment division fully exited with no material loss
Exports accelerating: 15%–20% of revenue, new geographies (Europe, Africa, US focus)
FY27 ₹2,000 crore target reaffirmed, not upgraded
Working capital stress and the inventory question
Short-term borrowing jumped to ₹28 crores from negligible levels in FY26. The MD attributed 75%–80% to order-backed inventory (a positive signal of demand) and 15%–20% to strategic raw material hedging against commodity volatility. The balance sheet remains strong by the company's account, and capex can be self-funded, but the speed of working capital deterioration deserves watching. If commodity prices stabilize faster than expected, inventory could overshoot and trap cash.
How the street is positioned
The stock sits at ₹1,370.7, down 22.56% from its all-time high of ₹1,770. That drawdown has nonetheless attracted fresh buying: foreign institutional ownership jumped 69 basis points to 1.06% (up from 0.37% in Q4 FY26), suggesting appetite for the dip. Domestic institutions trimmed by 216 basis points to 10.47%, possibly taking profits or rotating. Technicals remain neutral (RSI 37.9) with the stock trading below its 20-day (₹1,489.9) and 50-day (₹1,564.6) moving averages but comfortably above its 200-day (₹1,236.1). Volume has been increasing, indicating conviction behind the move. The street's own read: the pullback is real, but this is not a collapse-in-confidence moment — more a repricing for a quarter of less-than-expected margin leverage on strong topline growth.
Revenue growth (22.6% YoY) beats macro and is well-distributed across infrastructure, power, shipbuilding, defense
Exports (15%–20% of revenue) expanding into Europe, Africa, US; Middle East base (80%–85%) remains stable
Flares/Process Equipment division fully exited; strategic pruning successful
Capex guidance maintained within prior range (₹30–35 Cr FY27); next-2-year capex (₹60–70 Cr) shows commitment to automation
Net profit margin (7.7%) vs 12%–13% target shows execution gap; sequential decline (−2.4% QoQ) despite revenue growth is concerning
Margin recovery timing 'early days Q3' — vague and execution-risky
Working capital stress: ₹28 Cr short-term borrowing (vs negligible FY26); cycle deterioration if commodity volatility persists
FY27 ₹2,000 crore aspiration reaffirmed but H1 implies run-rate of ₹900–950 Cr; target looks overstated
M&A/automation strategy still exploratory ('ecosystem very tiny'); Fontech integration early-stage
Margin recovery timing execution
HighSequential PAT decline (−2.4% QoQ) despite revenue growth (+11.4%) shows price pass-through is not yet visible. 'Early days Q3' is vague; if recovery slips to Q4 or H2 FY28, earnings multiples will compress further. This is the linchpin of the bull case.
Commodity (steel, freight, PCB) volatility and pass-through uncertainty
High80% of margin dip attributed to costs beyond Ador's control. Global trends are macro-driven; pass-through depends on contract structures. Limited pricing power in commoditized segments could delay recovery indefinitely.
Working capital cycle deterioration
Medium₹28 Cr short-term borrowing (up from near-zero) is manageable but signals leverage. If commodity prices stabilize suddenly, inventory overshoot could trap cash. If volatility persists, borrowing could spiral.
FY27 ₹2,000 crore aspiration execution
MediumH1 revenue (₹654 Cr) implies a run-rate of ₹900–950 Cr for the full year at 22% growth, not ₹2,000 Cr. Either growth must nearly double or the target is a miss. Miss would dent credibility and trigger downgrades.
M&A/automation execution and overpayment
LowStrategy is sound (higher-margin segments, robotics, Fontech M&R), but the company is in exploratory mode. Risk of overpaying for small platforms or slow integration is real. No quantified pipeline or timeline.
Customer concentration in core segments
LowTop-50/100 customer deepening is underway, but wallet share remains limited. If a major customer (infra or power) shifts or capex cycle slows, revenue could face headwind. Diversification needs acceleration.
1 · Q3 FY27 margin recovery trajectory
Does OPM/EBITDA improve toward 12%–13% target as price hikes take effect? Sequential profit growth despite any commodity headwind is the test. If NPM stays below 8.5%, the execution risk is real and the bull case weakens.
2 · Export acceleration (Europe, Africa, US entry)
Are the new geographies ramping faster than expected? Export revenue is less commodity-exposed and higher-margin than core India welding. Momentum here (say, 25%+ growth) would offset domestic margin pressure and support the long-term case.
3 · Working capital normalization
Does ₹28 Cr borrowing stabilize or increase further as FY27 progresses? If it declines toward ₹15–20 Cr and inventory turns improve, it signals successful growth-stage management. Persistent elevation raises leverage concerns.
4 · Fontech M&R integration and margin contribution
Early hiring is underway; look for Q3/Q4 evidence of synergy capture. If Fontech contributes meaningfully to gross/EBITDA margin (as guided), it validates the M&A thesis. Slow integration would dent confidence.
5 · Shipbuilding and defense capex cycle traction
Are orders flowing? Infrastructure and defense are long-term tailwinds, but order book visibility will tell you whether the 20%+ growth momentum is real or inventory-driven.
ADOR Welding is not in crisis, but it is in transition. A 23% revenue top-line matched by a 7.7% net margin is not a sustainable combination; the company knows it, and the market is repricing for the gap. The inflation narrative is honest and credible, but the vagueness of 'early days Q3' margin recovery leaves room for disappointment.
The stock's 22% drawdown from its all-time high and the fresh FII buying suggest the market is treating this as a repricing, not a collapse. The long-term strategy — automation, exports, M&A into higher-margin segments — is sound and could support a 12%–13% EBITDA margin over a 2–3 year horizon. But the near-term (next 2–3 quarters) is execution risk.
The single number to track from here is sequential NPM in Q3. If it moves toward 9%–10%, the recovery narrative holds. If it stays flat or declines, the inflation excuse wears thin, and the stock likely tests support at ₹1,200–1,250 (the 200-day moving average zone). The Hold rating is fair; buyers are waiting for clarity, and holders are watching Q3 closely.
Informational and educational content only. Not investment advice.